biotech · Amyotrophic Lateral Sclerosis (ALS) · Amyotrophic Lateral Sclerosis · BCLI
BRAINSTORM CELL THERAPEUTICS
BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics is a biotech organization headquartered in NEW YORK, NY, USA. It trades on NYSE under ticker BCLI. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lat
NEW YORK, NY, USA HQ
2004 Founded
30 Employees
Public company Type
BCLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- NEW YORK, NY, USA
- Founded
- 2004
- Employees
- 30
- Programs
- 5
- Drugs
- 5
- Patents
- 8
Debamestrocel - MSC-NTF (NurOwn)
Phase 3 · mab · Amyotrophic Lateral Sclerosis (ALS)
Debamestrocel - MSC-NTF (NurOwn) for Amyotrophic Lateral Sclerosis (ALS) is a Phase 3 program (mab) at BRAINSTORM CELL THERAPEUTICS INC. with 1 ClinicalTrials.gov record(s).
Internal code BCT-006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BRAINSTORM CELL THERAPEUTICS INC.
- Phase
- Phase 3
- Modality
- mab
- Indication
- Amyotrophic Lateral Sclerosis (ALS)
- Status
- active
- Trials
- 1